Skip to main content
. Author manuscript; available in PMC: 2021 May 10.
Published in final edited form as: Sci Immunol. 2020 Jun 19;5(48):eabb1025. doi: 10.1126/sciimmunol.abb1025

Fig. 4. 3M-052 adjuvant formulated in PLGA NP’s with or without GLA significantly improves the magnitude and breadth of binding Ab responses against HIV-1 Env gp140, gp120 and V1V2 epitope bearing antigens in comparison with other adjuvants in the study.

Fig. 4.

Env antigen specific IgG Ab responses were measured using a binding antibody multiplex (BAMA) assay. Antibody responses are represented as area under the serum titration curve (AUTC) detailed in the methods section. Scatter plots represent % change in binding Ab responses from peak (week 20) to termination (~week 70) time points against; (A) autologous 1086.C gp140 Env antigen, (B) 1086.C gp120 Env antigen, (C) gp41 antigen and (D) 1086.C V1V2 tag antigen. (E) Binding Ab responses to various HIV-1 Env antigens (n=24) are summarized by Clade groups. (F) Line graphs show group average magnitude breadth curves highlighting breadth of binding activity against Env gp140 (n=7) and Env gp120 (n=8). Statistical differences are color coded to indicate the respective group comparisons. Statistical significance of differences in magnitude of immune responses was tested using a non-parametric Wilcoxon rank-sum test (also known as Mann-Whitney U test) using the R software version 3.6.1. **** p<0.0001: *** p<0.001: ** p<0.01, *p<0.05.